Phase II Study of Four Concentrations of Intraperitoneal NanoPac Plus Six Cycles of IV Carboplatin and Paclitaxel in Patients With Platinum-Sensitive Recurrent Stage III Epithelial Ovarian Cancer Undergoing Second Cytoreductive Surgery
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2019
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin; Paclitaxel
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nanology
- 10 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 09 Oct 2017 According to a Nanology media release, the first patient has been enrolled in this trial.